Anthoula Koliadi

Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

Kuchimanchi, Mita; Jorgensen, Trine Lembrecht; Hanze, Eva; Jain, Angela et al.

Part of Clinical Pharmacology in Drug Development, 2026

• DOI for Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial
• Download full text (pdf) of Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Ladjevardi, Cecilia Olsson; Skribek, Marcus; Koliadi, Anthoula; Rydén, Viktoria et al.

Part of Cancer Immunology and Immunotherapy, 2025

• DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
• Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; El-Naggar, Ali Inan et al.

Part of Frontiers in Oncology, 2024

• DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
• Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

Sköld, Camilla; Corvigno, Sara; Dahlstrand, Hanna; Enblad, Gunilla et al.

Part of Cancer Causes and Control, p. 1101-1109, 2024

• DOI for Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
• Download full text (pdf) of Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

Evaluation of a cervical cancer-specific restriction spectrum imaging model on an independent pilot cohort using PET/MRI: pre- and post-therapy

Lundström, Elin; Rodríguez-Soto, Ana E.; Hedlund, Elisabeth; Jónsdóttir, Björg et al.

Part of Proceedings of the International Society for Magnetic Resonance in Medicine 32nd Annual Meeting, Singapore, May 04-09, 2024, 2024

• Download full text (pdf) of Evaluation of a cervical cancer-specific restriction spectrum imaging model on an independent pilot cohort using PET/MRI: pre- and post-therapy

Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

Kuchimanchi, Mita; Jorgensen, Trine Lembrecht; Hanze, Eva; Jain, Angela et al.

Part of Clinical Pharmacology in Drug Development, 2026

• DOI for Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial
• Download full text (pdf) of Exposure-Response Relationship of Dostarlimab in Primary Advanced/Recurrent Endometrial Cancer: Results From Interim Analysis 2 of Part 1 of the RUBY Trial

Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Ladjevardi, Cecilia Olsson; Skribek, Marcus; Koliadi, Anthoula; Rydén, Viktoria et al.

Part of Cancer Immunology and Immunotherapy, 2025

• DOI for Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer
• Download full text (pdf) of Differences in immune-related toxicity between PD-1 and PD-L1 inhibitors: a retrospective cohort study in patients with advanced cancer

Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; El-Naggar, Ali Inan et al.

Part of Frontiers in Oncology, 2024

• DOI for Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness
• Download full text (pdf) of Multiple immune-related adverse events secondary to checkpoint inhibitor therapy in patients with advanced cancer: association with treatment effectiveness

Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

Sköld, Camilla; Corvigno, Sara; Dahlstrand, Hanna; Enblad, Gunilla et al.

Part of Cancer Causes and Control, p. 1101-1109, 2024

• DOI for Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer
• Download full text (pdf) of Association between parity and pregnancy-associated tumor features in high-grade serous ovarian cancer

The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis

Rydén, Viktoria; El-Naggar, Ali Inan; Koliadi, Anthoula; Ladjevardi, Cecilia Olsson et al.

Part of Pigment Cell & Melanoma Research, 2024

• DOI for The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis
• Download full text (pdf) of The role of dacarbazine and temozolomide therapy after treatment with immune checkpoint inhibitors in malignant melanoma patients: A case series and meta-analysis

Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Ladjevardi, Cecilia Olsson; Koliadi, Anthoula; Rydén, Viktoria; Inan El-Naggar, Ali et al.

Part of Cancer Medicine, p. 13217-13224, 2023

• DOI for Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study
• Download full text (pdf) of Predicting immune-related adverse events using a simplified frailty score in cancer patients treated with checkpoint inhibitors: A retrospective cohort study

Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes

Sköld, Camilla; Koliadi, Anthoula; Enblad, Gunilla; Stålberg, Karin et al.

Part of International Journal of Cancer, p. 773-781, 2022

• DOI for Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes
• Download full text (pdf) of Parity is associated with better prognosis in ovarian germ cell tumors, but not in other ovarian cancer subtypes

Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors

Valachis, Antonios; Rosén, Camilla; Koliadi, Anthoula; Digkas, Evangelos et al.

Part of Oncoimmunology, 2021

• DOI for Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors
• Download full text (pdf) of Improved survival without increased toxicity with influenza vaccination in cancer patients treated with checkpoint inhibitors

Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

Tholander, Bengt; Koliadi, Anthoula; Botling, Johan; Dahlstrand, Hanna et al.

Part of Upsala Journal of Medical Sciences, p. 325-329, 2020

• DOI for Complete response with combined BRAF and MEK inhibition in BRAF mutated advanced low-grade serous ovarian carcinoma.

High proliferation is associated with inferior outcome in male breast cancer patients

Nilsson, Cecilia; Koliadi, Anthoula; Johansson, Ida; Ahlin, Cecilia et al.

Part of Modern Pathology, p. 87-94, 2013

• DOI for High proliferation is associated with inferior outcome in male breast cancer patients

Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort

Niméus-Malmström, Emma; Koliadi, Anthoula; Ahlin, Cecilia; Holmqvist, Marit et al.

Part of International Journal of Cancer, p. 961-967, 2010

• DOI for Cyclin B1 is a prognostic proliferation marker with a high reproducibility in a population-based lymph node negative breast cancer cohort

Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer

Koliadi, Anthoula; Nilsson, Cecilia; Holmqvist, Marit; Holmberg, Lars et al.

Part of Acta Oncologica, p. 816-820, 2010

• DOI for Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer

The Prognostic Impact of Proliferation Markers in Breast Cancer with Emphasis on Cyclin B1 and PPH3

Koliadi, Anthoula

2014

• Download full text (pdf) of The Prognostic Impact of Proliferation Markers in Breast Cancer with Emphasis on Cyclin B1 and PPH3

Evaluation of a cervical cancer-specific restriction spectrum imaging model on an independent pilot cohort using PET/MRI: pre- and post-therapy

Lundström, Elin; Rodríguez-Soto, Ana E.; Hedlund, Elisabeth; Jónsdóttir, Björg et al.

Part of Proceedings of the International Society for Magnetic Resonance in Medicine 32nd Annual Meeting, Singapore, May 04-09, 2024, 2024

• Download full text (pdf) of Evaluation of a cervical cancer-specific restriction spectrum imaging model on an independent pilot cohort using PET/MRI: pre- and post-therapy

Correction of B₀-related distortions in diffusion-weighted images of malignant and normal cervical tissue

Lundström, Elin; Rodríguez-Soto, Ana E.; Conlin, Christopher; Loubrie, Stephane et al.

Part of Proceedings of the International Society for Magnetic Resonance in Medicine 32nd Annual Meeting, 2024

• Download full text (pdf) of Correction of B₀-related distortions in diffusion-weighted images of malignant and normal cervical tissue

Early experience of tumor detection and therapy response assessment in cervical cancer using advanced DWI in PET/MRI

Hedlund, Elisabeth; Lundström, Elin; Rodríguez-Soto, Ana E.; Jonsdottir, Björg et al.

Part of Abstracts - 30th European Symposium on Urogenital Radiology, 2024

• Download full text (pdf) of Early experience of tumor detection and therapy response assessment in cervical cancer using advanced DWI in PET/MRI

Association between parity, histopathological tumor features and survival in high-grade serous ovarian cancer

Sköld, Camilla; Tolf, Anna; Corvigno, Sara; Dahlstrand, Hanna et al.